Aeglea BioTherapeutics Stock Forecast, Price & News

+0.14 (+1.87 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume316,047 shs
Average Volume187,515 shs
Market Capitalization$373.38 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aeglea BioTherapeutics logo

About Aeglea BioTherapeutics

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.42 out of 5 stars

Medical Sector

158th out of 1,352 stocks

Pharmaceutical Preparations Industry

73rd out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aeglea BioTherapeutics (NASDAQ:AGLE) Frequently Asked Questions

Is Aeglea BioTherapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aeglea BioTherapeutics?

Wall Street analysts have given Aeglea BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aeglea BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aeglea BioTherapeutics' next earnings date?

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Aeglea BioTherapeutics

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its earnings results on Wednesday, August, 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.06. The biotechnology company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $6.45 million.
View Aeglea BioTherapeutics' earnings history

How has Aeglea BioTherapeutics' stock price been impacted by COVID-19?

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have increased by 41.4% and is now trading at $7.61.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AGLE?

4 equities research analysts have issued 12 month target prices for Aeglea BioTherapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Aeglea BioTherapeutics' share price to reach $15.67 in the next year. This suggests a possible upside of 105.9% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aeglea BioTherapeutics' key executives?

Aeglea BioTherapeutics' management team includes the following people:
  • Anthony G. Quinn, President, Chief Executive Officer & Director
  • Leslie Sloan, Chief Operating Officer
  • Jonathan D. Alspaugh, Chief Financial Officer (LinkedIn Profile)
  • Steven Weber, Chief Accounting Officer, VP & Controller
  • Scott W. Rowlinson, Vice President-Research

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aeglea BioTherapeutics' key competitors?

What other stocks do shareholders of Aeglea BioTherapeutics own?

When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.33%), Vanguard Group Inc. (4.27%), Nantahala Capital Management LLC (3.42%), Goldman Sachs Group Inc. (2.31%), Great Point Partners LLC (1.83%) and State Street Corp (1.54%). Company insiders that own Aeglea BioTherapeutics stock include Anthony G Quinn and Jonathan Alspaugh.
View institutional ownership trends for Aeglea BioTherapeutics

Which major investors are selling Aeglea BioTherapeutics stock?

AGLE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Northern Trust Corp, Vanguard Group Inc., California Public Employees Retirement System, and Russell Investments Group Ltd..
View insider buying and selling activity for Aeglea BioTherapeutics
or view top insider-selling stocks.

Which major investors are buying Aeglea BioTherapeutics stock?

AGLE stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Altium Capital Management LP, Millennium Management LLC, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Renaissance Technologies LLC, and State Street Corp. Company insiders that have bought Aeglea BioTherapeutics stock in the last two years include Anthony G Quinn, and Jonathan Alspaugh.
View insider buying and selling activity for Aeglea BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $7.61.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics has a market capitalization of $373.38 million and generates $3.89 million in revenue each year. The biotechnology company earns $-80,890,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

Aeglea BioTherapeutics employs 90 workers across the globe.

What is Aeglea BioTherapeutics' official website?

The official website for Aeglea BioTherapeutics is

Where are Aeglea BioTherapeutics' headquarters?

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 942-2935 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.